{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:17:56Z","timestamp":1791418676751,"version":"4.3.3"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jaad.2023.05.049","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T01:04:51Z","timestamp":1692061491000},"page":"S29-S32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"S","title":["Janus kinase inhibitors for alopecia areata"],"prefix":"10.1016","volume":"89","author":[{"given":"Brett A.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany G.","family":"Craiglow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jaad.2023.05.049_bib1","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1111\/jdv.16858","article-title":"Utility of azathioprine, methotrexate and cyclosporine as steroid-sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients","volume":"34","author":"Lai","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2023.05.049_bib2","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2023.05.049_bib3","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1172\/JCI31942","article-title":"Lymphocytes, neuropeptides, and genes involved in alopecia areata","volume":"117","author":"Gilhar","year":"2007","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.jaad.2023.05.049_bib4","first-page":"1043","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat\u00a0Med"},{"issue":"18","key":"10.1016\/j.jaad.2023.05.049_bib5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.05.049_bib6","unstructured":"King BA, Zhang X, Harcha G, et\u00a0al. Efficacy and safety of ritlecitinib (PF-06651600) in patients with alopecia areata and \u226550% scalp hair loss: results from the international Allegro phase 2b\/3 randomized, double-blind, placebo-controlled study. Paper presented at: Congress of the European Academy of Dermatology and Venereology; 2021; Virtual."},{"key":"10.1016\/j.jaad.2023.05.049_bib7","unstructured":"King BA. Top-line results from THRIVE-AA1: a phase 3 clinical trial of CTP-543 (deuruxolitinib), an oral JAK inhibitor, in adult patients with moderate to severe alopecia areata. Paper presented at: World Congress of Hair Research; 2022; Melbourne, Australia."},{"issue":"2","key":"10.1016\/j.jaad.2023.05.049_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study","volume":"82","author":"Olsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.049_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00403-022-02336-0","article-title":"A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata","volume":"315","author":"Mikhaylov","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.049_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","article-title":"Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients","volume":"78","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.049_bib11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jaad.2023.05.049_bib12","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","article-title":"A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19","volume":"39","author":"Bieber","year":"2022","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.049_bib13","doi-asserted-by":"crossref","first-page":"e15062","DOI":"10.1111\/dth.15062","article-title":"Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata","volume":"34","author":"Peterson","year":"2021","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.049_bib14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","article-title":"Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort","volume":"86","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.049_bib15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaad.2019.08.080","article-title":"Combination tofacitinib and oral minoxidil treatment for severe alopecia areata","volume":"85","author":"Wambier","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300988X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300988X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:28:23Z","timestamp":1759274903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222300988X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S019096222300988X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.05.049","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase inhibitors for alopecia areata","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.05.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}